Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 11 Aug 2022
European Commission approves Imbruvica (ibrutinib) fixed duration combination for adult patients with previously untreated chronic lymphocytic leukaemia
9 August 2022 - It is the first all oral, fixed duration, once daily treatment based on a Bruton's tyrosine kinase ...
Posted by Michael Wonder on 11 Aug 2022
Roche receives FDA approval for VENTANA MMR RxDx panel to identify dMMR solid tumour patients and pMMR endometrial cancer patients eligible for Keytruda
11 August 2022 - Based on cancer biomarkers, the first-of-its-kind VENTANA MMR RxDx Panel helps identify solid tumour patients, including endometrial ...
Posted by Michael Wonder on 10 Aug 2022
Failed COVIDSafe app deleted
10 August 2022 - The Albanese Government has acted to delete the wasteful and ineffective COVIDSafe app. ...
Posted by Michael Wonder on 10 Aug 2022
Real-world data can help expedite drug approvals for serious diseases with few options
10 August 2022 - My grandmother was diagnosed with dementia in the early 2000s. We started taking it seriously when she ...
Posted by Michael Wonder on 10 Aug 2022
The situation in New Zealand can only be described as dire
11 August 2022 - The available evidence for 2022 suggests the innovative pharmaceutical industry has very little interested in preparing/lodging ...
Posted by Michael Wonder on 10 Aug 2022
Cure Rare Disease receives FDA approval to administer first in human CRISPR therapeutic
10 August 2022 - Cure Rare Disease announces the approval from the US FDA to administer its very first therapeutic. ...
Posted by Michael Wonder on 10 Aug 2022
Overall survival, progression-free survival and tumour response benefit supporting initial US FDA approval and indication extension of new cancer drugs, 2003-2021
10 August 2022 - Clinical trial evidence is routinely evaluated for initial drug approvals, yet the benefit of indication extensions remains ...
Posted by Michael Wonder on 10 Aug 2022
EU regulator begins review of Pfizer-BioNTech's variant adapted COVID shot
9 August 2022 - The EMA has started a rolling review of a variant-adapted COVID-19 vaccine from Pfizer and BioNTech, ...
Posted by Michael Wonder on 10 Aug 2022
Few U.S. patients with hepatitis C get timely treatment, CDC says
9 August 2022 - Few U.S. adults diagnosed with hepatitis C virus infection receive timely treatment with anti-viral drugs, the ...
Posted by Michael Wonder on 10 Aug 2022
FDA authorises emergency use of Jynneos vaccine to increase vaccine supply
9 August 2022 - Today, the U.S. FDA issued an emergency use authorisation for the Jynneos vaccine to allow health care ...
Posted by Michael Wonder on 09 Aug 2022
Has the innovative pharmaceutical industry essential given up trying to list new medicines in New Zealand?
10 August 2022 - Upon examining the agenda for this month's PTAC meeting, one would think that it has. ...
Posted by Michael Wonder on 09 Aug 2022
Network collaborators announced for CADTH’s post-market drug evaluation network
8 August 2022 - CADTH is pleased to announce the successful collaborators of its inaugural Post-Market Drug Evaluation Network. ...
Posted by Michael Wonder on 09 Aug 2022
Challenges of health technology assessment in pluralistic healthcare systems: an ISPOR Council report
9 August 2022 - Health technology assessment has been growing in use over the past 40 years, especially in its impact ...
Posted by Michael Wonder on 09 Aug 2022
Paladin Labs announces Health Canada's filing acceptance of cenobamate tablets as an adjunctive therapy for the management of partial-onset seizures in adults with epilepsy
8 August 2022 - Paladin Labs announced today that Health Canada has accepted its new drug submission for cenobamate tablets as ...
Posted by Michael Wonder on 09 Aug 2022
Introducing CADTH’s RWE Guidance Working Group
9 August 2022 - CADTH is pleased to announce the introduction of the Real-World Evidence Guidance Working Group. ...